Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients
2019
Аутори
Ebrahimi, KeramatollahSabljak, Predrag
Simić, Aleksandar
Skrobić, Ognjan
Velicović, Dejan
Sljukić, Vladimir
Novaković, Ivana
Dobricić, Valerija
Micev, Marjan
Pasko, Predrag
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
BACKGROUND: /Aim. KIT (KIT proto-oncogene receptor tyrosine kinase) and PDGFRA (platelet-derived growth factor receptor alpha) gene mutations represent major molecular forces inside the gastrointestinal stromal tumors (GIST). Aim of this study was to evaluate these mutations in the patients who underwent surgical resection of gastric GIST, but without imatinib mesylate treatment. Methods. Retrospective clinical study included patients who were operated on due to gastric GIST from November 2000 till November 2016. A molecular analysis of paraffin embedded tumor tissue was performed, and the patients with the presence of KIT and PDGFRA mutations were further evaluated, with regard to the pathological tumor stage, disease recurrence and overall survival. Results. Out of 45 patients in total, 43 patients had KIT and PDGFRA mutations, and 2 patients were classified as the wild type GIST. After curative resection, 11 patients were classified as a low risk GIST, 8 as an intermediate risk and ...26 as a high risk GIST. The KIT mutations were present in 37 patients, most commonly as deletion in exon 11. The PDGFRA mutations were present in 6 patients. The presence of KIT mutation had a strong statistical correlation with the mitotic index (p = 0.021). After the ten-year follow-up, all patients with the PDGFRA mutations were alive, while those with the KIT mutations had a survival rate of 71% (p = 0.31). Conclusion. The presence of KIT exon 11 deletion in the patients with primarily resected gastric GIST is associated with the higher mitotic index and worse overall survival than those present with the PDGFRA mutations. This results suggest prognostic significance towards more aggressive behaviors.
Кључне речи:
gastrointestinal stromal tumors / genes / mutation / digestive system surgical procedures / neoplasm metastasis / prognosis / survivalИзвор:
Vojnosanitetski pregled, 2019, 76, 12, 1268-1273Издавач:
- Vojnomedicinska akademija - Institut za naučne informacije, Beograd
DOI: 10.2298/VSP180205048E
ISSN: 0042-8450
WoS: 000509954500009
Scopus: 2-s2.0-85079431647
Институција/група
Poljoprivredni fakultetTY - JOUR AU - Ebrahimi, Keramatollah AU - Sabljak, Predrag AU - Simić, Aleksandar AU - Skrobić, Ognjan AU - Velicović, Dejan AU - Sljukić, Vladimir AU - Novaković, Ivana AU - Dobricić, Valerija AU - Micev, Marjan AU - Pasko, Predrag PY - 2019 UR - http://aspace.agrif.bg.ac.rs/handle/123456789/5011 AB - BACKGROUND: /Aim. KIT (KIT proto-oncogene receptor tyrosine kinase) and PDGFRA (platelet-derived growth factor receptor alpha) gene mutations represent major molecular forces inside the gastrointestinal stromal tumors (GIST). Aim of this study was to evaluate these mutations in the patients who underwent surgical resection of gastric GIST, but without imatinib mesylate treatment. Methods. Retrospective clinical study included patients who were operated on due to gastric GIST from November 2000 till November 2016. A molecular analysis of paraffin embedded tumor tissue was performed, and the patients with the presence of KIT and PDGFRA mutations were further evaluated, with regard to the pathological tumor stage, disease recurrence and overall survival. Results. Out of 45 patients in total, 43 patients had KIT and PDGFRA mutations, and 2 patients were classified as the wild type GIST. After curative resection, 11 patients were classified as a low risk GIST, 8 as an intermediate risk and 26 as a high risk GIST. The KIT mutations were present in 37 patients, most commonly as deletion in exon 11. The PDGFRA mutations were present in 6 patients. The presence of KIT mutation had a strong statistical correlation with the mitotic index (p = 0.021). After the ten-year follow-up, all patients with the PDGFRA mutations were alive, while those with the KIT mutations had a survival rate of 71% (p = 0.31). Conclusion. The presence of KIT exon 11 deletion in the patients with primarily resected gastric GIST is associated with the higher mitotic index and worse overall survival than those present with the PDGFRA mutations. This results suggest prognostic significance towards more aggressive behaviors. PB - Vojnomedicinska akademija - Institut za naučne informacije, Beograd T2 - Vojnosanitetski pregled T1 - Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients EP - 1273 IS - 12 SP - 1268 VL - 76 DO - 10.2298/VSP180205048E ER -
@article{ author = "Ebrahimi, Keramatollah and Sabljak, Predrag and Simić, Aleksandar and Skrobić, Ognjan and Velicović, Dejan and Sljukić, Vladimir and Novaković, Ivana and Dobricić, Valerija and Micev, Marjan and Pasko, Predrag", year = "2019", abstract = "BACKGROUND: /Aim. KIT (KIT proto-oncogene receptor tyrosine kinase) and PDGFRA (platelet-derived growth factor receptor alpha) gene mutations represent major molecular forces inside the gastrointestinal stromal tumors (GIST). Aim of this study was to evaluate these mutations in the patients who underwent surgical resection of gastric GIST, but without imatinib mesylate treatment. Methods. Retrospective clinical study included patients who were operated on due to gastric GIST from November 2000 till November 2016. A molecular analysis of paraffin embedded tumor tissue was performed, and the patients with the presence of KIT and PDGFRA mutations were further evaluated, with regard to the pathological tumor stage, disease recurrence and overall survival. Results. Out of 45 patients in total, 43 patients had KIT and PDGFRA mutations, and 2 patients were classified as the wild type GIST. After curative resection, 11 patients were classified as a low risk GIST, 8 as an intermediate risk and 26 as a high risk GIST. The KIT mutations were present in 37 patients, most commonly as deletion in exon 11. The PDGFRA mutations were present in 6 patients. The presence of KIT mutation had a strong statistical correlation with the mitotic index (p = 0.021). After the ten-year follow-up, all patients with the PDGFRA mutations were alive, while those with the KIT mutations had a survival rate of 71% (p = 0.31). Conclusion. The presence of KIT exon 11 deletion in the patients with primarily resected gastric GIST is associated with the higher mitotic index and worse overall survival than those present with the PDGFRA mutations. This results suggest prognostic significance towards more aggressive behaviors.", publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd", journal = "Vojnosanitetski pregled", title = "Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients", pages = "1273-1268", number = "12", volume = "76", doi = "10.2298/VSP180205048E" }
Ebrahimi, K., Sabljak, P., Simić, A., Skrobić, O., Velicović, D., Sljukić, V., Novaković, I., Dobricić, V., Micev, M.,& Pasko, P.. (2019). Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients. in Vojnosanitetski pregled Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 76(12), 1268-1273. https://doi.org/10.2298/VSP180205048E
Ebrahimi K, Sabljak P, Simić A, Skrobić O, Velicović D, Sljukić V, Novaković I, Dobricić V, Micev M, Pasko P. Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients. in Vojnosanitetski pregled. 2019;76(12):1268-1273. doi:10.2298/VSP180205048E .
Ebrahimi, Keramatollah, Sabljak, Predrag, Simić, Aleksandar, Skrobić, Ognjan, Velicović, Dejan, Sljukić, Vladimir, Novaković, Ivana, Dobricić, Valerija, Micev, Marjan, Pasko, Predrag, "Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients" in Vojnosanitetski pregled, 76, no. 12 (2019):1268-1273, https://doi.org/10.2298/VSP180205048E . .